Chemotherapy With a Guidance System
Antibody-drug conjugates (ADCs) are among the most important advances in cancer treatment, combining the targeting precision of antibodies with the cell-killing power of chemotherapy. An ADC uses an antibody to home in on a protein found on cancer cells, then delivers a potent toxic payload directly to those cells — a smart bomb approach that concentrates the drug where it is needed while sparing much of the healthy tissue that conventional chemotherapy damages.
Why They Matter
Traditional chemotherapy circulates throughout the body, causing the side effects that make treatment so difficult. ADCs aim to widen the gap between effective dose and toxic dose by targeting delivery, allowing the use of payloads too potent to give systemically. This has produced meaningful benefits in cancers including certain breast, bladder, and lung cancers, and the number of approved ADCs and their applications is expanding rapidly.
An Expanding Arsenal
The field is advancing quickly with new targets, more sophisticated linker chemistry, and novel payloads, extending ADCs to more cancer types and earlier treatment lines. While not free of side effects and not universally effective, ADCs exemplify the shift toward precision oncology that delivers treatment more selectively. Their continued development is broadening options for many patients. Facilities can source lab supplies and pharmacy supplies from our catalog.
